Study on cannabis-like compounds for inflammatory arthritis
Part of Bones, joints & muscles, Digestive system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests whether plant-based compounds similar to cannabis (called phytocannabinoids) can help calm inflammation and improve immune function in people with certain types of arthritis or autoimmune diseases like lupus or Sjögren's disease. It aims to offer a new way to treat these conditions without the 'high' of marijuana.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a diagnosis of rheumatoid arthritis, psoriatic arthritis, or another immune-mediated inflammatory condition like lupus or Sjögren’s disease
- You are not currently using any cannabis products (including CBD oil) and agree to avoid them during the study
- You are not pregnant or breastfeeding
- You are on a stable dose of certain arthritis medications (e.g., methotrexate, biologics) or low-dose steroids (up to 15 mg/day of prednisone)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study examines joint tissue from people with different types of arthritis to understand the disease better. It may help researchers develop better treatments in the future.
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
This study looks at how diet affects people with different types of arthritis and related autoimmune conditions. If you are a UCF Health patient between 18 and 65, you may be able to help researchers learn more about which foods help or worsen symptoms.
This study looks at how your immune system responds to starting infliximab or adalimumab for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Results may help doctors understand why some people don’t respond as well and how to improve treatment.
This study looks at how a body signal called IL-23 may drive inflammation in spondyloarthritis (including joints) using samples from your care. It may help researchers identify which body cells and targets are involved, and how treatments could work better for active disease.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
Hear when a new Sjogren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.